Momenta Phama (MNTA) Announces Proposed $200M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 10, 2019 4:04 PM ESTCAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to purchase up to an additional $30,000,000 of shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Momenta.
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. Stifel is acting as a... More
